新的免疫疗法药物 Keyturda将头部和颈部癌症的 缓解期延长至五年 New immunotherapy drug Keytruda extends head and neck cancer remission to five years.

以Keytruda名义出售的免疫治疗药物Pemprolizumab在治疗头部和颈部癌症方面显示出巨大的好处,使这一疾病保持5年不变,而标准护理为30个月。 Immunotherapy drug Pembrolizumab, sold as Keytruda, has shown significant benefits in treating head and neck cancers, keeping the disease at bay for five years compared to 30 months with standard care. 药物的目标是一种叫PD-L1的蛋白质 增强免疫系统抗癌的能力 The drug targets a protein called PD-L1, enhancing the immune system's ability to fight cancer. 一项涉及714名病人的全球性试验发现,在Pembromizumab三年后罹患癌症的人中,该身体其他地方的癌症复发风险低10%。 A global trial involving 714 patients found that the risk of cancer returning elsewhere in the body was 10% lower among those on Pembrolizumab after three years. 这种治疗为这类癌症患者提供了延长无癌期的希望。 This treatment offers hope for longer cancer-free periods for patients with this type of cancer.